J2N-MC-JZNX: A phase 2 trial of pirtobrutinib in people with relapsed or refractory CLL/SLL

This trial aims to see how safe and effective pirtobrutinib is when given to people with chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) which has come after (relapsed) or not responded (refractory) to treatment.

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT06588478

Trial aim and background  

The aim of this trial is to see how safe and effective 3 different dose levels of the treatment pirtobrutinib is in people with relapsed or refractory CLL/SLL who have received a BTK inhibitor previously.

Pirtobrutinib is a type of targeted treatment called a BTK inhibitor. It blocks a protein called BTK. BTK is part of a pathway that helps B lymphocytes stay alive. 

Who can enter 

Adults with CLL/SLL who have received 1-3 prior lines of therapy including a BTK-inhibitor may be eligible for this trial.

Locations 

Recruitment is taking place at the following UK locations:

  • Beatson West of Scotland Cancer Centre, Glasgow
  • Clatterbridge Cancer Centre, Liverpool
  • Hammersmith Hospital, London
  • Heartlands Hospital, Birmingham
  • Lincoln County Hospital, Lincoln
  • Maidstone Hospital, Maidstone
  • Northwick Park Hospital, Harrow
  • Singleton Hospital, Swansea
  • St James's University Hospital, Leeds

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at:

https://clinicaltrials.gov/study/NCT06588478

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.